NO20000957L - Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer - Google Patents

Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer

Info

Publication number
NO20000957L
NO20000957L NO20000957A NO20000957A NO20000957L NO 20000957 L NO20000957 L NO 20000957L NO 20000957 A NO20000957 A NO 20000957A NO 20000957 A NO20000957 A NO 20000957A NO 20000957 L NO20000957 L NO 20000957L
Authority
NO
Norway
Prior art keywords
aminopyridines
substituted
branched alkoxy
nos inhibitors
inhibitors
Prior art date
Application number
NO20000957A
Other languages
English (en)
Norwegian (no)
Other versions
NO20000957D0 (no
Inventor
Iii John Adams Lowe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20000957D0 publication Critical patent/NO20000957D0/no
Publication of NO20000957L publication Critical patent/NO20000957L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20000957A 1997-08-28 2000-02-25 Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer NO20000957L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5773997P 1997-08-28 1997-08-28
PCT/IB1998/001223 WO1999011620A1 (fr) 1997-08-28 1998-08-11 2-aminopyridines alcoxy-substituees ramifiees, utilisees comme inhibiteurs de nos

Publications (2)

Publication Number Publication Date
NO20000957D0 NO20000957D0 (no) 2000-02-25
NO20000957L true NO20000957L (no) 2000-02-25

Family

ID=22012464

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000957A NO20000957L (no) 1997-08-28 2000-02-25 Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer

Country Status (32)

Country Link
US (2) US6362195B1 (fr)
EP (1) EP1007512B1 (fr)
JP (1) JP3441714B2 (fr)
CN (1) CN1268122A (fr)
AP (1) AP9801331A0 (fr)
AR (1) AR016644A1 (fr)
AT (1) ATE215532T1 (fr)
AU (1) AU8458698A (fr)
BR (1) BR9811921A (fr)
CA (1) CA2302436C (fr)
DE (1) DE69804635T2 (fr)
DK (1) DK1007512T3 (fr)
EA (1) EA200000165A1 (fr)
ES (1) ES2172173T3 (fr)
GT (1) GT199800135A (fr)
HN (1) HN1998000125A (fr)
HR (1) HRP980476A2 (fr)
HU (1) HUP0002803A2 (fr)
ID (1) ID24318A (fr)
IL (1) IL134302A0 (fr)
IS (1) IS5342A (fr)
MA (1) MA26538A1 (fr)
NO (1) NO20000957L (fr)
OA (1) OA11294A (fr)
PA (1) PA8458301A1 (fr)
PE (1) PE106699A1 (fr)
PL (1) PL339008A1 (fr)
PT (1) PT1007512E (fr)
SI (1) SI1007512T1 (fr)
TN (1) TNSN98157A1 (fr)
WO (1) WO1999011620A1 (fr)
ZA (1) ZA987788B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
SK1702001A3 (en) * 1998-08-11 2003-02-04 Pfizer Prod Inc New pharmaceutical uses for NOS inhibitors
CN1341099A (zh) * 1999-02-25 2002-03-20 辉瑞产品公司 含有稠合环取代基的2－氨基吡啶
WO2001009307A2 (fr) * 1999-07-30 2001-02-08 University College London Recherche systematique de modulateurs de synthase d'oxyde nitrique
EP1203098A2 (fr) * 1999-07-30 2002-05-08 University College London Criblage inductible pour la decouverte de medicaments
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
US6469172B2 (en) * 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
SE0102640D0 (sv) 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US20040077853A1 (en) * 2001-10-10 2004-04-22 Pfizer Inc. 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
EP1501511A4 (fr) * 2002-05-06 2006-06-07 Univ Washington Methodes de traitement du glaucome et d'autres etats induits par l'expression de nos-2 par inhibition de la voie egfr
WO2005007627A1 (fr) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. Derive de phenylpyridine, produit intermediaire correspondant, et herbicide contenant ledit derive de phenylpyridine en tant qu'ingredient actif
WO2006053109A1 (fr) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Composes heteroaryle
US8604031B2 (en) * 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP3002279A1 (fr) 2014-10-02 2016-04-06 Bayer CropScience AG Procédé de fabrication de dérivés de sulfure 3-(5-aminotriazolyl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
WO1996018616A1 (fr) * 1994-12-12 1996-06-20 Merck & Co., Inc. 2-aminopyridines substituees utilisees comme inhibiteurs de synthase d'oxyde d'azote
US5972975A (en) * 1995-12-08 1999-10-26 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
PT891332E (pt) 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina

Also Published As

Publication number Publication date
TNSN98157A1 (fr) 2005-03-15
BR9811921A (pt) 2000-08-15
ZA987788B (en) 2000-02-28
NO20000957D0 (no) 2000-02-25
AU8458698A (en) 1999-03-22
HUP0002803A2 (hu) 2001-06-28
ES2172173T3 (es) 2002-09-16
HN1998000125A (es) 1999-02-09
DE69804635T2 (de) 2002-07-18
GT199800135A (es) 2000-02-08
AP9801331A0 (en) 2000-02-27
PT1007512E (pt) 2002-07-31
OA11294A (en) 2003-10-22
PE106699A1 (es) 1999-11-02
AR016644A1 (es) 2001-07-25
ID24318A (id) 2000-07-13
HRP980476A2 (en) 1999-06-30
PA8458301A1 (es) 2000-05-24
EP1007512A1 (fr) 2000-06-14
EP1007512B1 (fr) 2002-04-03
US6362195B1 (en) 2002-03-26
WO1999011620A1 (fr) 1999-03-11
US20020022642A1 (en) 2002-02-21
CN1268122A (zh) 2000-09-27
SI1007512T1 (en) 2002-10-31
EA200000165A1 (ru) 2000-10-30
IL134302A0 (en) 2001-04-30
PL339008A1 (en) 2000-12-04
DE69804635D1 (de) 2002-05-08
CA2302436A1 (fr) 1999-03-11
IS5342A (is) 2000-01-14
JP2001514252A (ja) 2001-09-11
ATE215532T1 (de) 2002-04-15
MA26538A1 (fr) 2004-12-20
CA2302436C (fr) 2003-10-07
JP3441714B2 (ja) 2003-09-02
DK1007512T3 (da) 2002-07-08

Similar Documents

Publication Publication Date Title
NO20000957L (no) Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer
WO2003013484A3 (fr) Derives n-monoacyles de o-phenylenediamines, leurs analogues heterocycliques a six elements, et leur utilisation comme agents pharmaceutiques
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
TR200001279T2 (tr) Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler.
DK1076657T3 (da) Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
NO992821L (no) Ketobenzamider som calpain-inhibitorer
NZ509207A (en) Thiobenzimidazole derivative compounds, and usage as chymase activity inhibitors
MY107740A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
BG104138A (en) 2-aminopyridines containing substituents with condensed rings as nos inhibitors
BG103964A (en) SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS
NO996108L (no) 9-oksinerytromycinderivater
TR200103099T2 (tr) Fosfodiesteraz IVinhibitörü 1-amino triazoloc 4,3-a!kinazolin-5-on ve/veya-5-tionlar
DK0583485T3 (da) Ethanolaminderivater med sympathomimetiske og anti-pollakisuria-virkninger
NO934196L (no) N,N-disubstituerte arylcykloalkylaminer, deres salter, legemidler inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for deres fremstilling
DK0839041T3 (da) Salte af amidinderivater og cyclooxygenaseinhibitorer, deres fremstillingsmåde og anvendelse som medikamenter og farmaceutiske sammensætninger indeholdende disse
ATE384722T1 (de) Alkoxypyridinderivate
NO984740L (no) Isatinderivater som acetylcholinesteraseinhibitorer og analgetiske midler
TR200001452T2 (tr) Bifenilamidin türevleri.
DE69709933D1 (en) Aromatische amidinderivate als selektive thrombininhibitoren
NO964348L (no) CCK- eller gastrin-modulerende 5-hetrocykliske-1,5-benzodiazepiner
NO991230L (no) Trisykliske forbindelser for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer
NO982072L (no) Amidin- og isotioureaderivater som inhibitorer av nitrogenoksydsyntase
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
DK0880520T3 (da) Benzo[c]quinolinderivater, deres fremstilling af anvendelse som 5-alfa-reduktaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application